Scientists at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute of The Ohio State University Comprehensive Cancer Center are studying tissues collected within hours of death to gather clues as to why certain cancers are able to spread and evolve.
Researchers at City of Hope showed that patients over 65 receiving chemotherapy experienced significantly fewer treatment-related side effects when a multidisciplinary team of experts analyzed each case and introduced personalized interventions.
According to results from the PROpel phase III trial, Lynparza (olaparib) in combination with abiraterone had a significant positive effect on radiographic progression-free survival versus standard-of-care abiraterone as a first-line treatment for men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.
Researchers from Yale Cancer Center identified the Cancer and Aging Research Group calculator as an effective tool in assessing chemotherapy toxicity probability in geriatric patients.
A pilot program developed by researchers at Yale Cancer Center offering next day access for oncologic consultation for patients showed reduced wait times for initial access to cancer care and increased patient satisfaction, according to a new report.
The FDA granted 510(k) clearance to the Dayspring Lite treatment for lymphedema and venous disease.
The FDA granted Breakthrough Device designation to the Novilase Interstitial Laser System and its proposed indication for use: the focal destruction of malignant breast tumors in adult women seeking a breast conserving procedure.
The FDA granted Fast Track designation to Acelarin (NUC-1031), currently being evaluated in a phase III study, NuTide:121, for the first-line treatment of patients with advanced biliary tract cancer.
The FDA accepted for priority review the supplemental Biologics License Application for PD-1 inhibitor Libtayo (cemiplimab-rwlc), a monoclonal antibody, to treat patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.
The FDA issued a draft guidance, Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products.
